Vimarsana
Biggest News Aggregation in the World

Abbott Diagnostics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Abbott Diagnostics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Abbott Diagnostics Today - Breaking & Trending Today

Obicetrapib Works Synergistically with Ezetimibe in Statin Users, Study Finds - Vimarsana News

Obicetrapib Works Synergistically with Ezetimibe in Statin Users, Study Finds

Christie Ballantyne, MD, discusses new data from the ROSE2 trial examining the potential synergistic effects of obicetrapib with ezetimibe in high-intensity statin users.

Joint Commission appoints 2 new executives - Vimarsana News

Joint Commission appoints 2 new executives

The Joint Commission has appointed two new officers to their executive leadership team: Leslie Krohn, Chief Brand and Communications Officer, and Jason Miles, C

The Joint Commission Enterprise announces two officer - Vimarsana News

The Joint Commission Enterprise announces two officer

OAKBROOK TERRACE, Illinois, Dec. 19, 2023 (GLOBE NEWSWIRE) -- The Joint Commission Enterprise today announced two appointments to its executive...

Verv Technologies of Sudbury appoints John Simmons as board chair - Vimarsana News

Verv Technologies of Sudbury appoints John Simmons as board chair

Company says he has extensive board leadership experience and an exceptional track record in executive roles

Implementation of a high sensitivity cardiac troponin I assay and risk of myocardial infarction or death at five years: observational analysis of a stepped wedge, cluster randomised controlled trial - Vimarsana News

Implementation of a high sensitivity cardiac troponin I assay and risk of myocardial infarction or death at five years: observational analysis of a stepped wedge, cluster randomised controlled trial

Objective To evaluate the impact of implementing a high sensitivity assay for cardiac troponin I on long term outcomes in patients with suspected acute coronary syndrome. Design Secondary observational analysis of a stepped wedge, cluster randomised controlled trial. Setting 10 secondary and tertiary care centres in Scotland, UK. Participants 48 282 consecutive patients with suspected acute coronary syndrome. Myocardial injury was defined as any high sensitivity assay result for cardiac troponin I >99th centile of 16 ng/L in women and 34 ng/L in men. Intervention Hospital sites were rando...

Source: bmj.com